12:00 AM
 | 
Sep 02, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Alexion sales and marketing update

Alexion recalled a single lot of Orphan drug Soliris eculizumab due to the presence of visible particles in a limited number of vials distributed outside of the U.S. The company estimates the recalled lot represents about 1-2% of monthly vial consumption. Alexion said...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >